What Thymosin Alpha-1 actually is

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic extracts by Allan Goldstein. It modulates T-cell maturation and function, particularly Th1 differentiation, and has been studied across infectious disease, immune deficiency, and oncology contexts.¹

It is approved in more than 35 countries (including Italy, Brazil, China) for hepatitis B/C, chronic fatigue, and immune-deficient cancer adjunct use under the brand Zadaxin.² It is not FDA-approved in the US. At Luxbae we prescribe TA-1 as a compounded peptide for adults with recurrent infections, immunosenescence concerns, or autoimmune-leaning fatigue presentations.

At Luxbae, Thymosin Alpha-1 is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — T-cell function and TLR signaling

Modulates T-cell maturation, particularly Th1 differentiation; signals through TLR2 and TLR9 to influence innate-adaptive immune crosstalk.³

What the research shows

T-cell support. Documented effects on T-cell maturation and Th1 differentiation.¹

Antiviral adjunct. Approved internationally as adjunct in hepatitis B and C therapy.²

Immunosenescence. Studied in age-related immune decline contexts.

Side effects: Generally well-tolerated. Mild injection-site reactions, transient flushing, rare flu-like symptoms.

FDA note: Not FDA-approved in the US. Approved in 35+ countries as Zadaxin. Prescribed at Luxbae as compounded protocol under medical supervision.

Thymosin Alpha-1 FAQ

Why is this not FDA-approved in US?
Approval pathways differ internationally; commercial decisions rather than safety concerns.

Stack with antibiotics or antivirals?
Yes — adjunct, not replacement.

References

1. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
2. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004.
3. Camerini R, Garaci E. Historical review of thymosin α1 in infectious diseases. Expert Opin Biol Ther. 2015.